These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 17353569

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST).
    Vichinsky E, El-Beshlawy A, Al Zoebie A, Kamdem A, Koussa S, Chotsampancharoen T, Bruederle A, Gilotti G, Han J, Elalfy M.
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28296163
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
    Imran F, Phatak P.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):297-304. PubMed ID: 19670988
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D.
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [Abstract] [Full Text] [Related]

  • 29. Iron-chelating therapy for transfusional iron overload.
    Brittenham GM.
    N Engl J Med; 2011 Jan 13; 364(2):146-56. PubMed ID: 21226580
    [Abstract] [Full Text] [Related]

  • 30. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
    Taher AT, Temraz S, Cappellini MD.
    Expert Rev Hematol; 2013 Oct 13; 6(5):495-509. PubMed ID: 24083402
    [Abstract] [Full Text] [Related]

  • 31. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF.
    Clin Ther; 2007 May 13; 29(5):909-917. PubMed ID: 17697909
    [Abstract] [Full Text] [Related]

  • 32. Current status of iron overload and chelation with deferasirox.
    Choudhry VP, Naithani R.
    Indian J Pediatr; 2007 Aug 13; 74(8):759-64. PubMed ID: 17785900
    [Abstract] [Full Text] [Related]

  • 33. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
    Karnon J, Tolley K, Vieira J, Chandiwana D.
    Clin Drug Investig; 2012 Dec 13; 32(12):805-15. PubMed ID: 23026844
    [Abstract] [Full Text] [Related]

  • 34. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
    Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T.
    Br J Haematol; 2011 Aug 13; 154(3):387-97. PubMed ID: 21592110
    [Abstract] [Full Text] [Related]

  • 35. Long-term efficacy and safety of deferasirox.
    Cappellini MD.
    Blood Rev; 2008 Dec 13; 22 Suppl 2():S35-41. PubMed ID: 19059055
    [Abstract] [Full Text] [Related]

  • 36. Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
    Shirley M, Plosker GL.
    Drugs; 2014 Jun 13; 74(9):1017-27. PubMed ID: 24919862
    [Abstract] [Full Text] [Related]

  • 37. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ.
    Hemoglobin; 2008 Jun 13; 32(1-2):1-15. PubMed ID: 18274978
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
    Porter JB, Elalfy MS, Taher AT, Aydinok Y, Chan LL, Lee SH, Sutcharitchan P, Habr D, Martin N, El-Beshlawy A.
    Ann Hematol; 2013 Jan 13; 92(2):211-9. PubMed ID: 23086508
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial.
    Premawardhena A, Perera C, Wijethilaka MN, Wanasinghe SK, Rajakaruna RHMG, Samarasinghe RANKK, Williams S, Mettananda S.
    BMJ Open; 2024 Feb 08; 14(2):e077342. PubMed ID: 38331857
    [Abstract] [Full Text] [Related]

  • 40. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
    Ho WL, Chung KP, Yang SS, Lu MY, Jou ST, Chang HH, Yang YL, Lin DT, Lin KH.
    J Formos Med Assoc; 2013 Apr 08; 112(4):221-9. PubMed ID: 23537869
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.